Next Article in Journal
Correction: DeClercq, V.; et al. Association between Diet Quality and Adiposity in the Atlantic PATH Cohort. Nutrients 2017, 9, 1155
Next Article in Special Issue
Home Enteral Nutrition: Towards a Standard of Care
Previous Article in Journal
The Effect of Depressive Symptoms on the Association between Gluten-Free Diet Adherence and Symptoms in Celiac Disease: Analysis of a Patient Powered Research Network
Previous Article in Special Issue
Enteral Nutrition in the Management of Pediatric and Adult Crohn’s Disease
Open AccessArticle

Feasibility of a Lactobacillus casei Drink in the Intensive Care Unit for Prevention of Antibiotic Associated Diarrhea and Clostridium difficile

1
Alberta Health Services, 670 CSC Royal Alexandra Hospital, Edmonton, AB T5H 3V9, Canada
2
Department of Critical Care Medicine, Faculty of Medicine and Dentistry, Edmonton, AB T5H 3V9, Canada
3
Department of Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB T5H 3V9, Canada
*
Author to whom correspondence should be addressed.
Nutrients 2018, 10(5), 539; https://doi.org/10.3390/nu10050539
Received: 29 March 2018 / Revised: 17 April 2018 / Accepted: 20 April 2018 / Published: 26 April 2018
(This article belongs to the Special Issue Advances in Enteral Nutrition)
Background: Over 70% of patients are prescribed antibiotics during their intensive care (ICU) admission. The gut microbiome is dramatically altered early in an ICU stay, increasing the risk for antibiotic associated diarrhea (AAD) and Clostridium difficile infections (CDI). Evidence suggests that some probiotics are effective in the primary prevention of AAD and CDI. Aim: To demonstrate safety and feasibility of a probiotic drink in ICU patients. Methods: ICU patients initiated on antibiotics were recruited, and matched with contemporary controls. Study patients received two bottles daily of a drink containing 10 billion Lactobacillus casei which was bolused via feeding tube. Tolerance to probiotics and enteral nutrition, development of adverse events, and incidence of AAD was recorded. CDI rates were followed for 30 days post antibiotic treatment. Results: Thirty-two patients participated in the trial. There were no serious adverse events in the probiotic group, compared to three in the control group. AAD was documented in 12.5% of the probiotic group and 31.3% in the control group. One patient in the probiotic group developed CDI compared to three in the control group. Discussion: A probiotic containing drink can safely be delivered via feeding tube and should be considered as a preventative measure for AAD and CDI in ICU. View Full-Text
Keywords: ICU; diarrhea; Clostridium difficile; Lactobacillus casei drink ICU; diarrhea; Clostridium difficile; Lactobacillus casei drink
MDPI and ACS Style

Alberda, C.; Marcushamer, S.; Hewer, T.; Journault, N.; Kutsogiannis, D. Feasibility of a Lactobacillus casei Drink in the Intensive Care Unit for Prevention of Antibiotic Associated Diarrhea and Clostridium difficile. Nutrients 2018, 10, 539.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop